**CASE SUBMISSION FORM FOR THE ALL-IC REL TUMOUR BOARD Date: 2023** **January** **1.**

|  |  |  |
| --- | --- | --- |
| **BASELINE DATA, TIME-LINE** |  **BIOLOGICAL FEATURES** | **ADDITIONAL INFORMATION** |
| **First name:** ……..…. **Surname initial:** …**DOB:** **2000 January** **Sex: female****Country:** ………. **City:** ………**Hospital:** ……..**Submitting doctor:** …  | **Immunophenotype** **(latest findings, emphasis: CD19, 20, 22, 38):****BCP**. **Details:** …………  | **Relevant comorbidities:**……………**Toxicities, complications so far:**……….. |
| **Cytogenetics (latest findings):**………… |
| **First presentation 2000 January****Localisation:** ………**1st relapse** **2000 January****Time from finishing 1st line treatment:**... **years and** .... **months, late****Localisation:** **isolated medullar****Extra details:** ...….**2nd relapse 2000 January****Time from finishing 2nd line treatment**: ... **years and** .... **months****Localisation:** **isolated medullar****Extra details:** ……**Further relapses: 2000 January****Localisation:** **isolated medullar**……... | **Molecular genetics (latest findings):**………… |
| **TREATMENT SO FAR (protocols, arms, deviations)** | **Situation to discuss:** **protocol deviation due to toxicity/else** **other important points**: …..………**Treatment plan from own physicians:**…………   **Questions to the board:**· …· …· … |
| **Front line therapy and response to therapy:**………… **1st relapse therapy and response to therapy:**…………..  **2nd and subsequent rel. therapy and response to therapy:**…………..**Latest leukaemia-status** **Date: 2000 January****Residual disease:** marrow … % by **morphology** **Extramedull:** …….. **Extra details:** ... |
| **Cumulative anthracycline: …** mg/m2 doxorubicin equivalent |

|  |
| --- |
| **FREE TEXT OR TABLES, FIGURES TO DEMONSTRATE FURTHER DATA IF NEEDED** |
|   |  |